The specificity of JAK3 kinase inhibitors
- 15 February 2008
- journal article
- Published by American Society of Hematology in Blood
- Vol. 111 (4), 2155-2157
- https://doi.org/10.1182/blood-2007-09-115030
Abstract
PF-956980 is a selective inhibitor of JAK3, related in structure to CP-690550, a compound being evaluated in clinical trials for rheumatoid arthritis and prevention of allograft rejection. PF-956980 has been evaluated against a panel of 30 kinases, and found to have nanomolar potency against only JAK3. Cellular and whole blood activity of this compound parallels its potency and selectivity in enzyme assays. It was effective in vivo at inhibiting the delayed type hypersensivity reaction in mice. We compared 2 commercially available JAK3 inhibitors (WHI-P131 and WHI-P154) in the same panel of biochemical and cellular assays and found them to be neither potent nor selective for JAK3. Both were found to be nanomolar inhibitors of the EGF receptor family of kinases. As these compounds have been used in numerous publications in the transplant and autoimmune disease literature, their specificity should be considered when interpreting these results.Keywords
This publication has 7 references indexed in Scilit:
- JAK kinase inhibitorsDrug Discovery Today, 2004
- Therapeutic Potential of Janus Kinase 3 (JAK3) InhibitorsCurrent Pharmaceutical Design, 2004
- The Novel JAK-3 Inhibitor CP-690550 Is a Potent Immunosuppressive Agent in Various Murine ModelsAmerican Journal of Transplantation, 2004
- Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 InhibitorScience, 2003
- An epigenetic view of helper T cell differentiationNature Immunology, 2003
- Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD miceClinical Immunology, 2003
- Pharmacologic manipulation of a four day murine delayed type hypersensitivity modelInflammation Research, 1993